← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #405 OF 1,000 MOST-CITED

Review and evaluation for investigation

FDA cited this observation 49 times across 47 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices49
BY FISCAL YEAR
FY20254
FY20243
FY20237
FY20227
FY20215
FY20205
FY201910
FY20187
FY20171

How FDA worded it — real examples

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

Taiwan Surgical Corporation · Zhubei · Devices · 2025-09-04

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

Advanced Monitored Caregiving, Inc. · New York, New York · Devices · 2025-01-31

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

Vitrolife Inc. · San Diego, California · Devices · 2025-01-23

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

Neuronetrix Solutions, LLC · Louisville, Kentucky · Devices · 2024-11-07

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

North Coast Medical Inc · Morgan Hill, California · Devices · 2024-08-02

Not all complaints have been adequately reviewed and evaluated to determine whether an investigation is necessary.

Bio Med Sciences, Inc · Allentown, Pennsylvania · Devices · 2024-03-21

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →